Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN ® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

Published:2013-06-17 Issue:11 Volume:30 Page:1293-1297
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:Diabet. Med.

Author:

Bode B. W.¹,Buse J. B.²,Fisher M.³,Garg S. K.⁴,Marre M.⁵,Merker L.⁶,Renard E.⁷,Russell‐Jones D. L.⁸,Hansen C. T.⁹,Rana A.⁹,Heller S. R.¹⁰,

Affiliation:

1. Atlanta Diabetes Associates Atlanta GA USA

2. University of North Carolina School of Medicine Chapel Hill NC USA

3. Glasgow Royal Infirmary Glasgow UK

4. Barbara Davis Center for Childhood Diabetes Aurora CO USA

5. Bichat Claude Bernard Hospital Paris France

6. Diabetes und Nierenzentrum Dormagen Germany

7. Montpellier University Hospital Montpellier France

8. Royal Surrey County Hospital Guildford UK

9. Novo Nordisk A/S Søborg Denmark

10. University of Sheffield Sheffield UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dme.12243

Reference6 articles.

1. Evolution of Insulin Development: Focus on Key Parameters

2. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

3. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials

4. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

5. Insulin Degludec in Type 1 Diabetes

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal‐bolus insulin regimens in treat‐to‐target trials: A narrative review;Diabetic Medicine;2024-04-28

2. Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades;Current Diabetes Reviews;2024-01

3. Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study);Diabetes Technology & Therapeutics;2023-03-01

4. Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial;Diabetes Research and Clinical Practice;2023-02

5. C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial;Diabetes, Obesity and Metabolism;2022-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3